Shopping Cart
Remove All
Your shopping cart is currently empty
Farletuzumab (Synonyms: MORAb-003)
Catalog No. T76720 Copy Product Info
🥰Excellent
Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.
Farletuzumab
Copy Product Info🥰Excellent
Catalog No. T76720
Synonyms MORAb-003
Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.
Farletuzumab
Cas No. 896723-44-7
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $645 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,530 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research. |
| In vitro | In CHO-FR cells, Farletuzumab (MORAb-003; 0-10 µg/mL) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner[1]. In IGROV-1 cells (0.1-100 µg/mL; 1 h), Farletuzumab mediates tumor cytotoxicity in vitro through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)[1]. In CHO-FR cells (0-10 µg/mL), Farletuzumab inhibits the phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby blocking an FRα-mediated signaling pathway[1]. |
| Synonyms | MORAb-003 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | FOLR1/FRA |
| Molecular Weight | 145.36 kDa |
| Cas No. | 896723-44-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Farletuzumab | purchase Farletuzumab | Farletuzumab cost | order Farletuzumab | Farletuzumab in vitro | Farletuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.